Genta Incorporated to Present at Thomas Weisel Partners Growth Forum
BERKELEY HEIGHTS, N.J., Jun 13, 2002 /PRNewswire-FirstCall via COMTEX/ -- Genta Incorporated (Nasdaq: GNTA) announced today that Dr. Raymond P. Warrell, Jr., Genta's Chairman and CEO, will present at the Thomas Weisel Partners Growth Forum in Santa Barbara, CA. The presentation will take place on Monday, June 17, 2002 at 6:15 pm EST (3:15 pm PST).
A live audio webcast will be available during the presentation and archived for 30 days, and is accessible via the following link: veracast.com.
In addition to the company presentation, Dr. Warrell will participate in a panel discussion focusing on the FDA drug approval process. The panel is entitled "Are Approval Rates Increasing?" and will take place on Monday, June 17th, at 11:35 am EST (8:35 am PST).
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on anticancer therapy. The Company's research platform is anchored by DNA Medicines, particularly applications of antisense and decoy aptamers. Genasense(TM), the Company's lead compound, is currently in Phase 3 trials for melanoma, multiple myeloma, chronic lymphocytic leukemia, and non-small cell lung cancer. The drug is also being studied in Phase 2 trials for leukemia, lymphoma, and prostate and small cell lung cancers. Genta's drug pipeline also comprises a portfolio of small molecules, including Gallium Products for treatment of cancer and accelerated bone loss, and Androgenics Compounds for treatment of prostate cancer. Genta aims to become a direct marketer of its pharmaceutical products in North America. For more information about Genta, please visit our website at: genta.com .
The statements contained in this press release and the related webcast that will follow are not historical statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the expectations, beliefs, intentions or strategies regarding the future. Without limiting the foregoing, the words "anticipates," "believes," "expects," "intends," "may" and "plans" and similar expressions are intended to identify forward-looking statements. The Company intends that all forward-looking statements be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the Company's views as of the date they are made with respect to future events, but are subject to many risks and uncertainties, which could cause the actual results of the Company to differ materially from any future results expressed or implied by such forward-looking statements. For example, the results obtained in pre-clinical or clinical studies may not be indicative of results that will be obtained in future clinical trials, and delays in the initiation or completion of clinical trials may occur as a result of many factors. Further examples of such risks and uncertainties also include, but are not limited to: the obtaining of sufficient financing to maintain the Company's planned operations; timely development, receipt of necessary regulatory approvals, and acceptance of new products; the successful application of the Company's technology to produce new products; the obtaining of proprietary protection for any such technology and products; the impact of competitive products and pricing and reimbursement policies; and changing market conditions. The Company does not undertake to update forward-looking statements. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurances that the Company's expectations are correct. All forward looking statements are expressly qualified in their entirety by this cautionary statement and other factors detailed in the Company's reports filed with the Securities and Exchange Commission.
MAKE YOUR OPINION COUNT - Click Here tbutton.prnewswire.com
SOURCE Genta Incorporated
CONTACT: Tara Spiess, Director of Investor Relations and Corporate Communications of Genta Incorporated, +1-908-286-3980, info@genta.com; Media - Hala Bashir of Noonan-Russo Communications, +1-212-696-4455, ext. 356; IR - Isabel Cordova or Brian Korb of Trout Group, +1-212-477-9007, all for Genta Incorporated
URL: genta.com prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
-0-
KEYWORD: New Jersey INDUSTRY KEYWORD: BIO HEA |
